Introduction
============

*Helicobacter pylori* (HP) infection is one of the world\'s most common infections. HP, a Gram-negative bacteria, is a human pathogen that is transmitted from human to human, and causes chronic active gastritis in all colonized subjects. This infection can lead to peptic ulcers, atrophic gastritis, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. Therefore, HP is considered an infectious disease regardless of clinical severity ([@b1-etm-0-0-9024]).

Routes of transmission are considered: direct contact between subjects ([@b2-etm-0-0-9024]), contaminated water sources or food ([@b3-etm-0-0-9024]), zoonotic transmission and iatrogenic transmission during endoscopies and dental care ([@b6-etm-0-0-9024]).

HP, is an intensely studied bacteria and plays a very important role in the ethiopatogenesis of gastric cancer, possibly carried by more than half of the world population ([@b7-etm-0-0-9024]).

The latest data regarding HP infection in Europe are from 2018 where it is shown that the lowest infection prevalence was found in Northern Europe, while the highest was in Eastern and Southern Europe, up to 84% in Portugal and Poland ([@b8-etm-0-0-9024]). Another systematic review and meta-analysis published in 2016 showed that Africa had the highest pooled prevalence of HP infection (70.1%; 95% CI, 62.6-77.7), whereas Oceania had the lowest prevalence (24.4%; 95% CI, 18.5-30.4). Among individual countries, the prevalence of HP infection varied from as low as 18.9% in Switzerland (95% CI, 13.1-24.7) to 87.7% in Nigeria (95% CI, 83.1-92.2) ([@b9-etm-0-0-9024]).

A review regarding the HP infection prevalence trends in Europe over time from 1990 to 2014 was published in 2015. The study reviewed the prevalence of HP across 35 European countries using surveys of unselected population. It showed that the prevalence of HP was much lower in northern and western regions of Europe than in eastern and southern Europe. The review revealed a significant reduction in the prevalence of HP over time with an overall mean reduction of 3.1% per year. Statistics showed that HP prevalence increased over younger age groups, often sharply, but levelled off in many studies from ages of \~50 years onwards, especially in areas of high prevalence.

Regarding gastric cancer incidence in Europe, in the 15-year period from 1993 to 2007, there was also a moderate to large reductions over time in each of the 18 countries in which the studies were done ([@b10-etm-0-0-9024]).

The first report on prevalence of HP infection in Romania was published in 1990([@b11-etm-0-0-9024]). *Helicobacter*-like organisms were identified using histological staining from antral gastric mucosa: 72.8% in gastric ulcer, 69.6% in duodenal ulcer, 69.2% in bulbitis, 61% in chronic gastritis, 50% in gastric cancer and 34.3% in healthy controls.

Currently there are various methods used for HP detection in all categories of patients, but it is recommended to use only those methods that have high specificity and sensitivity. The IgG anti-HP antibodies have low sensitivity because they can persist in blood plasma in high levels for many years even after treatment. Studies show that levels of IgG anti-Hp antibodies in the serum do not predict the presence of macroscopic gastroduodenal diseases or the density of HP colonization in HP-infected dyspeptic patients. In addition, there are some levels which do not allow a precise determination of HP status ([@b12-etm-0-0-9024]). Thus, the presence of anti-HP antibodies in the serum indicates that the patient had contact with the bacteria, without being able to determine definately whether the infection still exists.

The specific objectives of this study were: i) to estimate the prevalence of HP exposure in dyspeptic patients who presented to the hospital from this northwestern region of the country; ii) to determine the association of the HP exposure with potential risk factors such as age, sex and the area of residence; iii) to analyze the epidemiological trends of HP infection prevalence in a symptomatic population in this region of Romania by comparing with previous published data.

Patients and methods
====================

### Study design and setting

A retrospective study was performed including 414 patients who attended a secondary center, 'Salvosan Ciobanca' Medical Center from Zalău, Salaj, Romania between 2014 and 2018.

### Participants

Patients with dyspeptic symptoms presented either by their own initiative or were referred by their general practitioners for evaluation of the presence of IgG anti-HP antibodies, were included in the study. There was no exclusion criteria.

### Variables

The main outcome measure was the serology test result for HP antibodies. As predictors, we collected data on age, sex, place of residence, and the year of serology test.

### Serology analysis

Serology testing was made using immunochromatographic Laboquiq and Intermedical test kit for IgG anti-HP antibodies, and a result of \>20 was considered positive. All tests were processed according to the manufacturer\'s recommendations. The data were collected from the hospital archives.

### Statistical analysis

Qualitative data are presented by counts and percentages, and normally distributed continuous data as means and standard deviation. Associations between qualitative variables were checked with Chi-square test. Comparisons between two groups regarding normally distributed continuous data were performed with independent samples t-test. Tests were presented as two-tailed P-value, of 0.05 level of confidence. The statistical analysis was made using the program R Environment for statistical computing and graphics (R Foundation for Statistical Computing, Vienna, Austria) version 3.2.1.

Results
=======

### Demographic characteristics of the study population

Of the 414 patients, 42.2% (175 patients) were from rural areas and 57.7% (239 patients) from urban places. Regarding sex distribution 63.8% were females (264 persons) and 36.2% males (150 persons). The mean age of the group was 45.89, ranging from 6 years to 97 years. The patients characteristics and the prevalence of infection are shown in [Table I](#tI-etm-0-0-9024){ref-type="table"}.

### Prevalence of HP infection

Of the 414 patients, 40.8% (n=169) had positive IgG anti-HP and 59.2% (n=245) had negative IgG anti-HP.

### HP prevalence by sex, age group and place of residence

In terms of the positivity of the tests, the percentages were about the same with a slightly higher values among males 41.33% versus females 40.53%. The differences were not statistically significant (P=0.87). There was a higher prevalence of the positivity in the rural area (42.29%) versus (39.75%) in the urban area, but with no statistically significant differences (P=0.6). The prevalence of infection according to sex and place of residence is displayed in [Fig. 1](#f1-etm-0-0-9024){ref-type="fig"}.

The group with negative tests had younger mean age with 2.26 (95% CI, 1.01-5.53) years, than the group with positive tests, a difference that did not reach the level of significance (P=0.176). [Fig. 2](#f2-etm-0-0-9024){ref-type="fig"} shows the test result distribution according to age and sex.

Discussion
==========

The present study shows that \>40% of dyspeptic patients had or have HP infection. Comparing these values with those of previous studies on the prevalence of HP infection from the same region, it seems that they are declining. In medical literature there is no clear country wide recent data on this topic.

There are some interesting studies regarding the pediatric population and HP infection from Romania. In 2002, an epidemiological study was performed on dyspeptic children from northwestern region of Romania. The authors included 267 subjects, aged between 5-18 years, and the presence of infection was considered if both urease test and histological staining revealed the infection. The results showed a high prevalence of infection of 40% ([@b16-etm-0-0-9024]). In our study, from 16 patients \<18 years, 3 of them (1.7%) had a positive HP infection test.

One year later, in 2003, another study by Miller *et al* was published regarding the seroprevalence of antibodies to HP in Romanian adopted children, with age between 4 months and 16 years. A high prevalence was found for Romanian children of 20% ([@b17-etm-0-0-9024]).

A similar study published in 2018 also reported a high prevalence of HP infection among pediatric population (almost 25%) from 7,100 children studied from Cluj-Napoca, Romania ([@b18-etm-0-0-9024]).

An epidemiological study on asymptomatic subjects, from the western part of the county, Timisoara, using a serological test, found high rates of infection in the adult population in 2003. The study population consisted of 960 employees, and it was standardized for age and sex distribution of the western region population. The prevalence of HP infection in the adult population was 68.5%. The prevalence by age group were: 18-30 years, 65.3%; in group 31-40 years, 71.6%; in group 41-50 years, 75%; and in group 51-60 years, 88.7% ([@b19-etm-0-0-9024]). Even though the study was done on a smaller population (416 vs. 960), comparing the data, to our study the prevalence of HP infection was lower, as follows: in the group age 18-30 years, 10.6%; in group 30-40 years, 20.7%; in group 40-50 years, 24.2%; and in group 50-60 years, 23.6%.

In 2008 a study targeting the prevalence of HP infection was done in Cluj-Napoca including 955 patients. The global prevalence was 29.7%. The highest prevalence was seen in the age group \>80 years (42.8%), followed by the group 21-30 years (38.8%) and the group 41-50 years (35.9%). Also, the prevalence of HP infection was significantly higher in rural areas ([@b20-etm-0-0-9024]).

In a study published in 2014 by Ciobanu *et al* ([@b23-etm-0-0-9024]), a comparison regarding the data on HP epidemics from Romania was made to see if the tendency of the prevalence was decreasing. The first comparison was made in the same category of age, in different periods of time. The second comparison followed the prevalence trends over 15 years in the same population. In the group of children, a 10% decreased prevalence was noted from 1994 to 2003. Also, in young adults (20-30 years) from 1994 until 2009, the prevalence dropped significantly from 78.1% ([@b21-etm-0-0-9024]) to 51.7% ([@b22-etm-0-0-9024]). A similar prevalence was observed in the youngest group, followed over time: 50% in 1994, without a significant increase in 2009: 51.71%. For this age group, the rate of infection in adult life is very small. These data may reflect the first epidemiological trends of decreasing prevalence of infection in Romania.

Our data show a small difference between patients with HP infection from urban areas compared with rural areas. In urban areas people are more likely to have a higher education and easier access to medical care.

In a study from 2017 made in Craiova on 1,525 dyspeptic patients, in which the prevalence of HP infection was 63.67%, there were no significant percentage differences of the HP infection between the patients from urban area and those from rural area ([@b24-etm-0-0-9024]). In the study the prevalence of HP infection increased with age, the percentages by age groups were: age \<20 years, 2.16%; group 20-29 years, 12.36%; group 30-39 years, 16.7%; group 40-49 years, 17.1%; group 50-59 years, 20.7%; and in group 60-60 years, 17.9%. Comparing the data with those of the present study, the global prevalence (63.67 vs. 40.8%) and the prevalence in all age groups were lower. The epidemiological trends of HP prevalence in Romania is presented in [Table II](#tII-etm-0-0-9024){ref-type="table"}.

We argue that this decrease in the prevalence of HP infection over time could be attributed to better socio-economic conditions. The fact that patients have easier access to medical services, that more investigation are made when they show various dyspeptic symptoms and due to the existence of non-invasive methods of diagnosing this infection (serology, stool samples, respiratory test), with a more rapid treatment could explain the decreasing trends.

This decreasing prevalence of HP infection is correlated with the evolution of gastric cancer. An epidemiological study published in 2018, regarding the gastric cancer mortality in Romania, in period 1955-2012 shows a decreasing trend in both sexes; from 17.8% in 1990 to 15.2% in 2008 and 13% in 2012. Regarding gastric cancer incidence in period 2008-2012 it seems to be increased in males from 15.9% in 2008 to 16.3% in 2012 and appears to be stabilized in females; 5.8% in 2008 with the same value in 2012([@b25-etm-0-0-9024]).

Our study has several limitations. First, we would have preferred a larger sample, but routine HP screening is not usual in this area. Secondly, as data were collected from HP testing registry, we were not able to record detailed symptoms, the history of HP infection, the followed treatment, and the endoscopic findings. Therefore, further studies should be undertaken. A more detailed analysis on epidemiological trends in Romania in this region, over the last 30 years will be of great interest. However, the present results bring novel information on HP infection prevalence in this area, which was the main objective of our study.

This study shows that, among dyspeptic patients from Northwestern part of Romania, \>40% have or had a positive HP infection. Comparing our results with those of previous studies on the prevalence of HP infection from the same region, we were able to signal a decline in prevalence in HP infection over a 30-year interval.
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###### 

Prevalence of infection and patients characteristics.

  Test                        All (n=414)             Positive (n=169)   Negative (n=245)   P-value
  --------------------------- ----------------------- ------------------ ------------------ ---------
  Age (years), mean (SD)      45.89 (17.24)           47.22 (15.27)      44.97 (18.45)      0.176
  Age groups (years), n (%)                                                                 0.015
       \<18                   16 (3.86)               3 (1.78)           13 (5.31)           
       18-29                  59 (14.25)              18 (10.65)         41 (16.73)          
       30-39                  85 (20.53)              35 (20.71)         50 (20.41)          
       40-49                  92 (22.22)              41 (24.26)         51 (20.82)          
       50-59                  71 (17.15)              40 (23.67)         31 (12.65)          
       60-69                  47 (11.35)              14 (8.28)          33 (13.47)          
       ≥70                    44 (10.63)              18 (10.65)         26 (10.61)          
  Sex, n (%)                  18-29: 59/414 (14.25)                                         0.873
       Female                 264 (63.77)             107 (63.31)        157 (64.08)         
       Male                   150 (36.23)             62 (36.69)         88 (35.92)          
  Place of residence, n (%)                                                                 0.604
       Urban                  239 (57.73)             95 (56.21)         144 (58.78)         
       Rural                  175 (42.27)             74 (43.79)         101 (41.22)         

SD, standard deviation.

###### 

Epidemiological trends of HP prevalence among symptomatic patients in Nortwestern Romania.

  Population age (years)   Prevalence (%)   Reported year   Refs.                   Methodology
  ------------------------ ---------------- --------------- ----------------------- -----------------------------
  \<20                     50               1994            ([@b21-etm-0-0-9024])   Urease test
  21-30                    78.1             1994            ([@b21-etm-0-0-9024])   Urease test
  31-40                    85.9             1994            ([@b21-etm-0-0-9024])   Urease test
  41-50                    80.3             1994            ([@b21-etm-0-0-9024])   Urease test
  71-80                    61.5             1994            ([@b21-etm-0-0-9024])   Urease test
  5-18                     40               2003            ([@b19-etm-0-0-9024])   Urease test and histology
  18-30                    65.3             2003            ([@b19-etm-0-0-9024])   Urease test and histology
  31-40                    71.6             2003            ([@b19-etm-0-0-9024])   Urease test and histology
  41-50                    75               2003            ([@b19-etm-0-0-9024])   Urease test and histology
  21-30                    51.71            2009            ([@b22-etm-0-0-9024])   C14-Urease breath test
  \<20                     63.7             2017            ([@b24-etm-0-0-9024])   Urease test and IgG anti-HP
  20-29                    66.22            2017            ([@b24-etm-0-0-9024])   Urease test and IgG anti-HP
  50-69                    61.78            2017            ([@b24-etm-0-0-9024])   Urease test and IgG anti-HP
  21-30                    38.8             2018            ([@b20-etm-0-0-9024])   Urease test
  41-50                    35.9             2018            ([@b20-etm-0-0-9024])   Urease test
  \>80                     42.9             2018            ([@b20-etm-0-0-9024])   Urease test
  \<18                     1.78             2019            Our study               IgG-anti-HP
  18-30                    10.65            2019            Our study               IgG-anti-HP
  31-40                    20.7             2019            Our study               IgG-anti-HP
  41-50                    24.26            2019            Our study               IgG-anti-HP
  \>70                     10.65            2019            Our study               IgG-anti-HP

[^1]: *Abbreviations:* HP, *Helicobacter pylori*
